These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 27779227)

  • 1. Prostate cancer: Exosomal AR-V7 is a marker of hormonal therapy resistance.
    Fenner A
    Nat Rev Urol; 2016 Dec; 13(12):695. PubMed ID: 27779227
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 Oct; 196(4):1124. PubMed ID: 27628794
    [No Abstract]   [Full Text] [Related]  

  • 3. Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.
    Crumbaker M; Savdie R; Joshua AM
    Eur Urol; 2018 May; 73(5):736-737. PubMed ID: 29162351
    [No Abstract]   [Full Text] [Related]  

  • 4. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.
    Sartor O; Dong Y
    Asian J Androl; 2015; 17(3):439-40. PubMed ID: 25532583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Anand AU; Bjartell A
    Eur Urol; 2015 Feb; 67(2):349-50. PubMed ID: 25760252
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Taneja SS
    J Urol; 2015 Feb; 193(2):538. PubMed ID: 25617272
    [No Abstract]   [Full Text] [Related]  

  • 9. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
    De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
    Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
    Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
    Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR-V7 Protein in Circulating Tumor Cells-The Decider for Therapy?
    Montgomery RB; Plymate SR
    JAMA Oncol; 2016 Nov; 2(11):1450-1451. PubMed ID: 27261766
    [No Abstract]   [Full Text] [Related]  

  • 13. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: predicting resistance-AR-V7 is a potential biomarker.
    Stone L
    Nat Rev Urol; 2014 Nov; 11(11):606. PubMed ID: 25266571
    [No Abstract]   [Full Text] [Related]  

  • 15. HoxB13 mediates AR-V7 activity in prostate cancer.
    Navarro HI; Goldstein AS
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6528-6529. PubMed ID: 29891672
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer: Enzalutamide--differential cross resistance with taxanes.
    Fenner A
    Nat Rev Urol; 2015 Feb; 12(2):64. PubMed ID: 25534993
    [No Abstract]   [Full Text] [Related]  

  • 17. Has the PROPHECY of AR-V7 Been Fulfilled?
    De Laere B; Ost P; Grönberg H; Lindberg J
    J Clin Oncol; 2019 Aug; 37(24):2181-2182. PubMed ID: 31265360
    [No Abstract]   [Full Text] [Related]  

  • 18. AR-V7 detection guides treatment.
    Romero D
    Nat Rev Clin Oncol; 2018 Sep; 15(9):533. PubMed ID: 30018408
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical decision-making with AR-V7.
    Thoma C
    Nat Rev Urol; 2019 Dec; 16(12):694. PubMed ID: 31690843
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer: Targeting apoptosis resistance in CRPC.
    Thoma C
    Nat Rev Urol; 2016 Nov; 13(11):631. PubMed ID: 27725637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.